AstraZeneca (AZN) Tops Q4 EPS by 71c; initiates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
AstraZeneca's earnings top estimates but shares fall on core operating profit drop
February 8, 2024 6:41 AM ESTAstraZeneca (NASDAQ: AZN) shares fell more than 6% in premarket trading Thursday after the drugmaker reported notably lower-than-expected core operating profit for the fourth quarter.
Earnings per share (EPS) came in at $1.45 in Q4, topping the forecasted $0.74. The pharmaceutical giant generated a quarterly revenue of $12.02 billion, also above the consensus estimate of $12 billion.
Core operating profit rose 5.4% year-over-year to $2.75 billion, but was... More
Deutsche Bank Downgrades AstraZeneca (AZN) to Hold
February 8, 2024 5:37 AM ESTDeutsche Bank analyst Emmanuel Papadakis downgraded AstraZeneca (NASDAQ: AZN) from Buy to Hold.
The analyst comments "Q4 is a thoroughly underwhelming end to 2023 with a soft print that missed in most of the places that matter (Enhertu included, again), whilst FY24 guidance is... More
